InsiderTrades

Form 4 for IBRX ImmunityBio, Inc.

Accepted 2024-01-03 00:00:00 ET · period of report 2023-12-31 · accession 0001326110-24-000008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-01-03 2023-12-31 IBRX Sachs David C. CFO F - Tax $5.02 -10.5K 141.9K -7% -$52.8K
D 2024-01-03 2023-12-31 IBRX Sachs David C. CFO M - OptEx $0.00 +30.4K 152.4K +25% $0
D 2024-01-03 2023-12-31 IBRX Sachs David C. CFO M - OptEx $0.00 -30.4K 106.4K -22% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-12-31 F D 10,511 $5.02 141,928 D — — (F1) On December 31, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 29, 2023 was the settlement price used to calculate the shares withheld.
2 Common Common Stock 2023-12-31 M A 30,397 $0.00 152,439 D — —
3 Derivative Restricted Stock Units 2023-12-31 M D 30,397 $0.00 106,396 D — · — to — 30,397 Common Stock (F2) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F3) 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.